In short
This article discusses a clinical trial investigating the effects of influenza vaccination on inflammation in patients with stable coronary artery disease. The study aims to assess how the flu vaccine impacts systemic inflammatory markers, particularly high-sensitivity C-reactive protein (hsCRP), in this specific patient population. The trial is designed as a randomized delayed-start pilot study, comparing immediate vaccination to delayed vaccination after one month.
At a glance
- Study Type
- Randomized delayed-start pilot trial
- Main Objective
- Evaluate impact of influenza vaccination on systemic inflammatory response (hsCRP) in stable coronary artery disease patients
- Participants
- Patients ≥60 years with stable coronary artery disease
- Intervention
- Quadrivalent inactivated influenza vaccine for 2024-2025 season
- Primary Outcome
- Change in hsCRP levels at 1 month post-vaccination
- Secondary Outcomes
- Other inflammatory markers, arterial vulnerability markers, immune cell characterization, antibody titers
- Study Duration
- 1 month follow-up per participant
- Potential Impact
- May lead to larger studies on cardiovascular benefits of flu vaccination in coronary artery disease patients
Introduction
A new clinical trial is underway to investigate the effects of an influenza vaccine on patients with stable coronary artery disease. This article will provide detailed information about the vaccine and the study, using simple language to help patients understand the research being conducted.
Vaccine Composition
The vaccine being studied is called VAXIGRIPTETRA, which is a quadrivalent inactivated influenza vaccine. Quadrivalent means it protects against four different strains of the influenza virus. Inactivated means the vaccine contains killed virus particles, which cannot cause infection but can still stimulate an immune response.
The vaccine includes the following components:
- B/Phuket/3073/2013-like virus (wild type)
- Influenza virus B/Michigan/01/2021
- Influenza A/Victoria/4897/2022 IVR-238 (H1N1), inactivated
- Influenza virus A/California/122/2022 SAN-022 (H3N2) strain (split, inactivated)
These components represent different strains of influenza viruses that are expected to circulate during the 2024-2025 flu season.
Purpose of the Study
The main objective of this study is to evaluate how the influenza vaccine affects systemic inflammation in patients with stable coronary artery disease. Systemic inflammation refers to inflammation throughout the body, which can be measured by certain blood markers.
Specifically, the researchers aim to:
- Measure the impact of influenza vaccination on inflammation markers after one month
- Assess the vaccine's effect on markers of arterial vulnerability
- Characterize the immune response in circulating blood cells after vaccination
- Evaluate the relationship between vaccine-induced antibody responses and inflammation levels
Eligibility Criteria
To participate in this study, patients must meet certain criteria:
Inclusion criteria:
- Age 60 years or older
- Documented stable coronary artery disease
- Ability to comply with study requirements
- Willingness to provide informed consent
Exclusion criteria:
- History of serious reactions to influenza vaccines
- Recent influenza vaccination (within 6 months)
- Recent acute infections or worsening of chronic diseases
- Severe cognitive disorders
- Certain pre-existing medical conditions or medications affecting the immune system
- Recent or planned cardiovascular surgeries
Study Design
The study is designed as a randomized, delayed-start pilot trial. This means:
- Participants will be randomly divided into two groups
- The experimental group will receive the influenza vaccine immediately after enrollment
- The control group will receive the vaccine after a one-month delay
- Blood samples will be taken at the start of the study and after one month
- The vaccine will be administered as a deep subcutaneous injection in the deltoid muscle (upper arm)
Expected Outcomes
The primary outcome the researchers will measure is the level of high-sensitivity C-reactive protein (hsCRP) in the blood. HsCRP is a marker of inflammation in the body. Other outcomes include:
- Levels of other inflammatory markers such as interleukin-6, interleukin-1b, and tumor necrosis factor-α
- Markers of arterial vulnerability, including apolipoprotein B and lipoprotein(a)
- Characteristics of immune cells in the blood
- Antibody levels against the vaccine strains
Potential Benefits
While the specific benefits of this study are yet to be determined, the research aims to understand how influenza vaccination might affect inflammation in patients with coronary artery disease. If significant benefits are found, this study could lead to larger trials examining the potential cardiovascular benefits of influenza vaccination in this patient population.
Conclusion
This clinical trial represents an important step in understanding how influenza vaccination might affect patients with stable coronary artery disease. By studying the vaccine's impact on inflammation and immune responses, researchers hope to gain insights that could potentially improve care for these patients in the future.